New Pill Shows Promising Results Against Advanced Pancreatic Cancer

Here's something that could genuinely matter to you or someone you love: a new pill is showing real results against one of the deadliest cancers out there — pancreatic cancer — and for the first time in decades, doctors are actually getting emotional about it.

The drug is called daraxonrasib (say: da-rax-ON-ra-sib), and it just cleared a major hurdle in a large clinical trial. Researchers reported that a novel pill helped people with advanced pancreatic cancer live longer, raising hopes of long-needed better treatments for one of the deadliest types of cancer.

So why is this a big deal? Pancreatic cancer is among the most deadly forms in large part because it's hard to detect before it starts spreading to other organs. The American Cancer Society estimates about 67,000 new cases will be diagnosed in the U.S. this year and more than 52,000 people will die from the disease. The five-year overall survival rate is just 13%.

Here's how the drug works in plain English: Daraxonrasib blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades. Think of it like a broken traffic light stuck on green, constantly telling cancer cells to grow. This pill essentially jams that signal.

The numbers from the trial are striking. The daily pills nearly doubled survival time, with fewer severe side effects, in a study that randomly assigned the experimental drug or more chemotherapy to 500 patients whose metastatic — or spreading — cancer had quit responding to prior treatment. Specifically, those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients. While that may seem like a small improvement, the lead researcher said it marked the first drug to show a substantial advantage over chemotherapy.

To put that in perspective: unlike other cancers that have benefitted from a variety of chemotherapy alternatives, pancreatic cancer has been harder to tackle. This is the first time a drug has meaningfully beaten chemo in this context. One oncologist who has treated the disease for 16 years said she started crying when she first saw the results.

The findings were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.

Importantly, this isn't a cure. "While not curing the cancer, it is a very large step forward," said Dr. Zev Wainberg of UCLA, who helped lead the study. But researchers believe it could become a new standard of care, and they're already exploring whether it might work even earlier in the disease — potentially shrinking tumors enough to qualify more patients for surgery.

What about side effects? The side effects most likely to affect pill usage were a rash that can be severe and mouth sores. Still, those are generally considered more manageable than traditional chemotherapy.

If you or someone close to you has been diagnosed, there's a path opening up right now. The drug's maker, Revolution Medicines, funded the study, and the FDA plans to expedite review of the drug. Meanwhile, the agency is allowing what's called "expanded access" — meaning eligible patients can apply to get the drug before it's formally approved. Oncologists are already being flooded with requests as the special access program gets started.

The bottom line: this isn't a miracle cure, and it's not available at your pharmacy yet. But for a disease that has resisted nearly every treatment advance for decades, a pill that roughly doubles survival time — in pill form, no less — is a genuine breakthrough worth paying attention to.